157 related articles for article (PubMed ID: 36383618)
21. Sezary syndrome: cutaneous immunoperoxidase double-labeling technique demonstrates CD4/CD8 ratio non-specificity.
Balfour EM; Glusac EJ; Heald P; Talley LL; Smoller BR
J Cutan Pathol; 2003 Aug; 30(7):437-42. PubMed ID: 12859741
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors and evaluation of mycosis fungoides and Sézary syndrome.
Toro JR; Stoll HL; Stomper PC; Oseroff AR
J Am Acad Dermatol; 1997 Jul; 37(1):58-67. PubMed ID: 9216524
[TBL] [Abstract][Full Text] [Related]
23. Improvement in peripheral blood disease burden in patients with Sézary syndrome and leukemic mycosis fungoides after total skin electron beam therapy.
Klein RS; Dunlop JD; Samimi SS; Morrissey KA; Evans KG; Gardner JM; Introcaso CE; Vittorio CC; Rook AH; Micaily B; Kim EJ
J Am Acad Dermatol; 2013 Jun; 68(6):972-7. PubMed ID: 23415461
[TBL] [Abstract][Full Text] [Related]
24. A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome.
Benton EC; Crichton S; Talpur R; Agar NS; Fields PA; Wedgeworth E; Mitchell TJ; Cox M; Ferreira S; Liu P; Robson A; Calonje E; Stefanato CM; Wilkins B; Scarisbrick J; Wain EM; Child F; Morris S; Duvic M; Whittaker SJ
Eur J Cancer; 2013 Sep; 49(13):2859-68. PubMed ID: 23735705
[TBL] [Abstract][Full Text] [Related]
25. Image-guided lymph node core-needle biopsy predicts survival in mycosis fungoides and Sézary syndrome.
Calvani J; de Masson A; de Margerie-Mellon C; de Kerviler É; Ram-Wolff C; Gruber A; Meignin V; Brice P; Sadoux A; Mourah S; Bagot M; Battistella M
Br J Dermatol; 2021 Aug; 185(2):419-427. PubMed ID: 33400272
[TBL] [Abstract][Full Text] [Related]
26. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sézary syndrome.
Papadavid E; Economidou J; Psarra A; Kapsimali V; Mantzana V; Antoniou C; Limas K; Stratigos A; Stavrianeas N; Avgerinou G; Katsambas A
Br J Dermatol; 2003 Apr; 148(4):709-18. PubMed ID: 12752128
[TBL] [Abstract][Full Text] [Related]
27. Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center.
Geller S; Lebowitz E; Pulitzer MP; Horwitz SM; Moskowitz AJ; Dusza S; Myskowski PL
J Am Acad Dermatol; 2020 Aug; 83(2):430-439. PubMed ID: 31499157
[TBL] [Abstract][Full Text] [Related]
28. Flow cytometric evaluation of peripheral blood for suspected Sézary syndrome or mycosis fungoides: International guidelines for assay characteristics.
Horna P; Wang SA; Wolniak KL; Psarra K; Almeida J; Illingworth AJ; Johansson U; Craig FE; Torres R
Cytometry B Clin Cytom; 2021 Mar; 100(2):142-155. PubMed ID: 32319723
[TBL] [Abstract][Full Text] [Related]
29. Flow cytometric DNA ploidy analysis of peripheral blood from patients with sezary syndrome: detection of aneuploid neoplastic T cells in the blood is associated with large cell transformation in tissue.
Wang S; Li N; Heald P; Fisk JM; Fadare O; Howe JG; McNiff JM; Smith BR
Am J Clin Pathol; 2004 Nov; 122(5):774-82. PubMed ID: 15491974
[TBL] [Abstract][Full Text] [Related]
30. Molecular detection of circulating Sezary cells in patients with mycosis fungoides: could it predict future development of secondary Sezary syndrome? A single-institution experience.
Hutchinson CB; Stoecker M; Wang FF; Papalas J; Sebastian S; Burchette J; Datto M; Wang E
Leuk Lymphoma; 2012 May; 53(5):868-77. PubMed ID: 22044137
[TBL] [Abstract][Full Text] [Related]
31. Large cell transformation of Sézary syndrome. A conventional and molecular cytogenetic study.
So CC; Wong KF; Siu LL; Kwong YL
Am J Clin Pathol; 2000 Jun; 113(6):792-7. PubMed ID: 10874879
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome.
Kim YH; Bishop K; Varghese A; Hoppe RT
Arch Dermatol; 1995 Sep; 131(9):1003-8. PubMed ID: 7661601
[TBL] [Abstract][Full Text] [Related]
33. Histopathologic staging at initial diagnosis of mycosis fungoides and the Sézary syndrome. Definition of three distinctive prognostic groups.
Sausville EA; Eddy JL; Makuch RW; Fischmann AB; Schechter GP; Matthews M; Glatstein E; Ihde DC; Kaye F; Veach SR
Ann Intern Med; 1988 Sep; 109(5):372-82. PubMed ID: 3408055
[TBL] [Abstract][Full Text] [Related]
34. The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.
Pileri A; Guglielmo A; Grandi V; Violetti SA; Fanoni D; Fava P; Agostinelli C; Berti E; Quaglino P; Pimpinelli N
Cells; 2021 Oct; 10(10):. PubMed ID: 34685762
[TBL] [Abstract][Full Text] [Related]
35. Large Cell Transformation of Oral Mycosis Fungoides.
Sultan AS; Mostoufi B; Papadimitriou JC; Koka R; Basile J; Younis RH
Head Neck Pathol; 2018 Jun; 12(2):247-251. PubMed ID: 28741231
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases.
Benner MF; Jansen PM; Vermeer MH; Willemze R
Blood; 2012 Feb; 119(7):1643-9. PubMed ID: 22160616
[TBL] [Abstract][Full Text] [Related]
37. Heterogeneity of T-cell receptor expression at transformation in mycosis fungoides/Sezary Syndrome (MF/SS).
Jothishankar B; Venkataraman G; Goldberg RC; Abdulla F
Ann Diagn Pathol; 2019 Dec; 43():151404. PubMed ID: 31629155
[No Abstract] [Full Text] [Related]
38. Recognizing large-cell transformation of mycosis fungoides.
Herrmann JL; Hughey LC
J Am Acad Dermatol; 2012 Oct; 67(4):665-72. PubMed ID: 22261416
[TBL] [Abstract][Full Text] [Related]
39. Sézary syndrome and mycosis fungoides flow cytometric evaluation: The clinicians' perspective.
Guitart J
Cytometry B Clin Cytom; 2021 Mar; 100(2):129-131. PubMed ID: 32017375
[TBL] [Abstract][Full Text] [Related]
40. CD25+ folliculotropic Sézary syndrome with CD30+ large cell transformation.
Jang MS; Kang DY; Han SH; Park JB; Kim ST; Suh KS
Australas J Dermatol; 2014 Feb; 55(1):e4-8. PubMed ID: 23190349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
